| Overview |
| bs-19463R-PE |
| PSMC3 Polyclonal Antibody, PE Conjugated |
| WB |
| Human, Mouse, Xenopus laevis |
| Dog, Cow, Horse |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PSMC3 |
| 212-220/439 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5702 |
| P17980 |
| Cytoplasm, Nucleus |
| 26S protease regulatory subunit 6A; 26S proteasome AAA-ATPase subunit RPT5; Human immunodeficiency virus tat transactivator binding protein 1; MGC8487; Proteasome (prosome macropain) 26S subunit ATPase 3; Proteasome 26S ATPase subunit 3; Proteasome 26S subunit ATPase 3; Proteasome subunit P50; PRS6A_HUMAN; PSMC 3; PSMC3; Tat binding protein 1; TAT-binding protein 1; TBP-1; TBP1. |
| The 26S protease is involved in the ATP-dependent degradation of ubiquitinated proteins. The regulatory (or ATPase) complex confers ATP dependency and substrate specificity to the 26S complex (By similarity). In case of HIV-1 infection, suppresses Tat-mediated transactivation. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz